Acute myeloid leukemia (AML) is a blood cancer that remains mainly incurable. The high incidence of relapse is the big challenge. There is clear evidence that the metabolism in AML is frequently altered and adapts during disease progression. Patients differ in the metabolism of different tumor clones and their immune microenvironment (e.g. macrophages, T cells, NK cells, and stromal cells). The microenvironment can also act as driver of disease. This provides alternative treatment options for therapy. The MetaboTargetAML consortium will generate the first metabolism roadmap of AML to study cancer clones, immune cells and their metabolism in response to drug treatments. This will be used to generate AI-driven models to identify metabolic vulnerabilities as new treatment targets that will next be validated experimentally. This project will identify novel (metabolic) therapeutic targets and/or biomarkers for AML diagnostics and personalized medicine.

2025

2028